{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T15:18:26Z","timestamp":1778167106659,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.urolonc.2022.09.028","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:45:44Z","timestamp":1669178744000},"page":"62-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Should grade group 1 prostate cancer be reclassified as \u201cnon-cancer\u201d? A pathology community perspective"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0324-7178","authenticated-orcid":false,"given":"Ming","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samson W.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farshid","family":"Siadat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajal B.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.urolonc.2022.09.028_bib0001","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1470-2045(12)70388-1","article-title":"Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"issue":"35","key":"10.1016\/j.urolonc.2022.09.028_bib0002","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2012.44.0586","article-title":"Gleason score 6 adenocarcinoma: should it be labeled as cancer?","volume":"30","author":"Carter","year":"2012","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.urolonc.2022.09.028_bib0003","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.urolonc.2022.09.028_bib0004","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming Gleason score 6 prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.028_bib0005","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.juro.2017.11.067","volume":"199","author":"Hassan","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.028_bib0006","first-page":"16","article-title":"Gleason 6 prostate cancer: serious malignancy or toothless lion?","volume":"28","author":"Lepor","year":"2014","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.028_bib0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00345-020-03583-4","article-title":"Should Grade Group 1 (GG 1) be called cancer?","volume":"40","author":"Labbate","year":"2022","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.09.028_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MOU.0000000000000945","article-title":"Is Grade Group 1 (Gleason score 3\u200a+\u200a3\u200a=\u200a6) adenocarcinoma of the prostate really cancer?","volume":"32","author":"Epstein","year":"2022","journal-title":"Curr Opin Urol"},{"issue":"15","key":"10.1016\/j.urolonc.2022.09.028_bib0009","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1001\/jama.2009.1498","article-title":"Rethinking screening for breast cancer and prostate cancer","volume":"302","author":"Esserman","year":"2009","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.urolonc.2022.09.028_bib0010","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1016\/S1470-2045(13)70598-9","article-title":"Addressing overdiagnosis and overtreatment in cancer: a prescription for change","volume":"15","author":"Esserman","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.09.028_bib0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MOU.0000000000000165","article-title":"Should Gleason 6 be labeled as cancer?","volume":"25","author":"Kulac","year":"2015","journal-title":"Curr Opin Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.09.028_bib0012","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1464-410X.2011.10854.x","article-title":"Should we really consider Gleason 6 prostate cancer?","volume":"109","author":"Nickel","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.09.028_bib0013","unstructured":"National Comprehensive Care Network. Prostate Cancer (Version 4.2022). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed July 18, 2022."}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922003568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:11Z","timestamp":1761042431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922003568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1078143922003568"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.028","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should grade group 1 prostate cancer be reclassified as \u201cnon-cancer\u201d? A pathology community perspective","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}